Gut‐derived hormones are currently utilized in the clinical management of metabolic diseases, exemplified by glucagon‐like peptide‐1 receptor (GLP‐1R) agonists such as semaglutide and liraglutide, as well as GLP‐1/GIP (glucose‐dependent insulinotropic polypeptide) dual agonists like tirzepatide. Here, GLP1R is linked to metabolic disease.